Subscribe To

Price Alert Latest News Economic Calendar News

KRTX / Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON--( BUSINESS WIRE )--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Bill Meury, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. PST (12:00 p.m. EST). Read More

Demo Live Account See Partner Details

Content Topics

Karuna

Therapeutics

Present

41st

Annual

Morgan

Healthcare

Conference

Stock

KRTX

Posted: Jan 3 2023, 06:30

Author Name: Business Wire

KRTX News

By Zacks Investment Research
November 3, 2023

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.

By Seeking Alpha
October 16, 2023

Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. The stock h

By Business Wire
October 4, 2023

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative

By Zacks Investment Research
September 29, 2023

Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studi

By Seeking Alpha
August 24, 2023

Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT

Submission of New Drug Application of KarXT for the treatment of schizophrenia is expected in Q3, 2023. If FDA approval of KarXT is given for the trea

By Seeking Alpha
August 16, 2023

Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)

Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizop

By Seeking Alpha
August 5, 2023

Karuna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Call Transcript

Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Alexis Smith - Senior Directo

By Zacks Investment Research
August 4, 2023

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2

Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.